Development of a monoclonal anti-ADAMTS-5 antibody that specifically blocks the interaction with LRP1

11Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The potent aggrecanase ADAMTS-5 is constitutively secreted by chondrocytes, but it is rapidly endocytosed in normal cartilage via the cell surface endocytic receptor LRP1. Therefore it is difficult to detect the total ADAMTS-5 activity produced. In this study, we isolated a monoclonal anti-ADAMTS-5 antibody 1B7 that blocks LRP1-mediated internalization without affecting the aggrecanolytic activity. Addition of 1B7 to cultured human chondrocytes revealed the full aggrecanolytic activity of ADAMTS-5 generated by the cells. 1B7 is a useful tool to estimate the ADAMTS-5 activity and to identify its potential roles in the tissues.

Cite

CITATION STYLE

APA

Santamaria, S., Fedorov, O., McCafferty, J., Murphy, G., Dudhia, J., Nagase, H., & Yamamoto, K. (2017). Development of a monoclonal anti-ADAMTS-5 antibody that specifically blocks the interaction with LRP1. MAbs, 9(4), 595–602. https://doi.org/10.1080/19420862.2017.1304341

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free